An increasing number of decision makers now require economic support for reimbursing and listing new products, specifically in relation to their impact at the local level.
With the majority of regulatory submissions still based on core global data, there is a pressing need for best practice guidance on customizing key results for individual markets. An IMS symposium at ISPOR's 8th Annual European Congress in November focused specifically on issues around the transfer of economic evaluations and potential solutions for generating estimates that are applicable to local situations. Early, forward planning and flexible, transparent modelling that is responsive to local requirements for reimbursement were particularly underscored.
You can also download the full set of 64 abstracts of all presentations and posters involving IMS Health expertise or information at ISPOR's 8th Annual European Congress here.